Loading
TAMPA — Oragenics Inc. (symbol: ORNI) appointed John Bonfiglio as its new president and CEO this week. Based in Tampa, Oragenics manufactures and sells biopharmaceutical health products and antibiotics.
Oragenics will be the fifth company that Bonfiglio has led as CEO. Just last October, La Jolla, Calif.-based Transdel Pharmaceuticals Inc. appointed Bonfiglio to its chief executive position.
Bonfiglio has also led Durham, N.C.-based Argos Therapeutics; The Immune Response Corp., based in Carlsbad, Calif.; and Tustin, Calif.-based Peregrine Pharmaceuticals Inc.
“My focus will be to shepherd the company's technologies through the various stages of testing to eventual commercialization and to expand the company's sales of Probiora3 probiotics,” Bonfiglio says in a prepared statement.
“I am also committed to seeking out new sources of financing, and the possible outlicensing of other company-owned therapeutic platforms,” he adds.
Oragenics generated $1.1 million in revenues in its four most recent quarters of business, according to Yahoo Finance.
Your free article limit has been reached this month.
Subscribe now for unlimited digital access to our award-winning business news.
Join thousands of executives who rely on us for insights spanning Tampa Bay to Naples.
